Redesign Health

Redesign operates a hybrid venture studio and investment model. It originates some companies internally—matching founders with institutional partners and technology—and invests in others through venture capital and buyout strategies. The firm's proprietary AI knowledge graph aggregates millions of hours of expert research and institutional relationships to identify opportunities, making sourcing a systematic, data-driven process rather than a purely network-based one.

It functions as both. Redesign describes itself as a 'venture and applied technology platform,' combining elements of a venture studio (creating companies internally), a venture capital investor (backing external founders), and a buyout investor (acquiring existing healthcare businesses). This blended structure is designed to attack healthcare inefficiency from multiple angles simultaneously.

In 2023, Redesign Health and Sanabil Investments—a Saudi Arabian sovereign-linked investment entity—announced a partnership to launch the Sanabil Venture Studio by Redesign Health. The collaboration focuses on building and backing healthcare companies in Saudi Arabia and the broader Middle East, with Nuxera AI emerging as an early example, securing $2.5 million in seed funding from the venture studio.

Redesign targets the frontier where healthcare delivery, artificial intelligence, and digital infrastructure intersect. Confirmed focus areas include aging-in-place and payer-focused platforms (DUOS), surgical triage (Corvus), hospital financial operations (Translucent), heart failure management (Linea), and post-hospital care (Cascala Health). The firm seeks companies that rewire clinical, operational, or financial workflows with AI.

The knowledge graph aggregates internal expert research and hundreds of thousands of relationships across the healthcare ecosystem. Redesign's investment and company-building teams use it to match founders with institutional partners, identify technology-commercialization opportunities, and connect capital with specific healthcare problems. The firm treats this infrastructure as a plug-in resource that portfolio companies can access from formation through exit.

Yes, in the studio model, Redesign embeds its commercial and technical team alongside founders from investment through exit. The firm provides domain expertise, institutional introductions, and a deployment apparatus that functions as an extension of the portfolio company's own operations. This is distinct from the traditional venture capital model of board-level oversight with limited operational involvement.